This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.


  • Research type

    Research Study

  • Full title

    Investigation of molecular forms of ANP and BNP in patients with heart failure treated with ACE inhibitor and following switch to sacubitril valsartan.



  • Contact name

    Iain Squire

  • Contact email

  • Sponsor organisation

    University of Leicester

  • Duration of Study in the UK

    2 years, 0 months, 6 days

  • Research summary

    The recent PARADIGM-HF trial in chronic heart failure (CHF) demonstrated the superiority of the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril valsartan (Entresto), compared to the current gold-standard ACE (Angiotensin Converting Enzyme)inhibitor, on the composite end point of cardiovascular mortality or hospitalisation for heart failure. The mechanism of action of Entresto is thought to include increase in plasma levels of natriuretic peptides (NP); however the precise changes in circulating NP levels elicited by Entresto are unknown; thus the precise mechanism by which Entresto confers prognostic benefit in CHF is unclear. This observational cohort study will investigate circulating plasma levels of natriuretic peptides in patients taking an ACE inhibitor and then after switch to Entresto. The study period will run for a period of 4-6 weeks however the switch to Entresto will be clinically indicated, and not made for the purpose of this research.

  • REC name

    East Midlands - Leicester Central Research Ethics Committee

  • REC reference


  • Date of REC Opinion

    11 May 2017

  • REC opinion

    Favourable Opinion